The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.
Dexcom Announces Preliminary and Unaudited Revenue For Fourth Quarter and Fiscal Year 2023
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours